GI Cancer

February 18, 2022

Codebreak100 evaluates the efficacy of sotorasib in colorectal cancer previously treated with kras p.g12c mutation

Paper recently published in The Lancet Oncology demonstrates that sotorasib may be a therapeutic strategy for heavily pretreated patients with KRAS p.G12C mutated metastatic CRC, whose […]
February 18, 2022

Choice of first line treatment for advanced hepatocellular carcinoma

In this edition of his monthly column, Tiago Biachi, M.D. Advanced Fellow of Gastrointestinal Oncology at Memorial Sloan Kettering Cancer Center, discusses controversies in first-line treatment […]
February 18, 2022

Advanced Esophageal Squamous-Cell Carcinoma gains new treatment options

For decades, despite the poor survival outcomes, the standard treatment for advanced or metastatic esophageal squamous-cell carcinoma was based on chemotherapy (i.e. fluoropyrimidine plus platinum). However, […]
July 7, 2021

CheckMate 648: first-line immunotherapy as a new standard of care for advanced esophageal SCC

Nivolumab demonstrated superior overall survival versus chemotherapy in patients with previously treated esophageal squamous cell carcinoma, according to ATTRACTION-3 data. At ASCO 2021, immunotherapy efficacy data were released in the first–line setting of Checkmate […]
July 6, 2021

Updated efficacy and safety data from the CheckMate 577 trial

Nivolumab is known to demonstrate significant improvement in disease-free survival versus placebo in patients with resected stage II/III esophageal cancer with residual pathologic disease after neoadjuvant chemoradiotherapy, according to a recent publication in NEJM  […]
July 2, 2021

Final KEYNOTE 177 overall survival data for MSI-H/dMMR metastatic colorectal cancer

Pembrolizumab versus chemotherapy showed progression-free survival improvement in the second provisional analysis in patients with the tumor. The study continued until the final overall survival (OS) analysis, planned after 190 OS events […]
April 26, 2021

Neoadjuvant cemiplimab for the treatment of resectable hepatocellular carcinoma demonstrates pathological complete response rates

Neoadjuvant immunotherapy can induce pathological responses and immunological memory in different malignancies, being a potential therapy for hepatocellular carcinoma   A multi-cohort, phase II study (NCT03916627) of neoadjuvant cemiplimab (an anti-PD-1 antibody) for the treatment […]
April 20, 2021

Combination of avelumab, trastuzumab and mFOLFOX6 demonstrates clinical activity in metastatic gastroesophageal adenocarcinoma with HER2 amplification

Trastuzumab is a monoclonal antibody directed to HER2, indicated in combination with chemotherapy in 20 to 30% metastatic esophageal or gastric adenocarcinomas that overexpress HER2. However, the […]
April 5, 2021

Circulating hybrid cells are evaluated as a biomarker of treatment response in patients with rectal and esophageal cancers

The team previously demonstrated that circulating hybrid cells (CD45-positive/CK-positive) are found in high numbers in pancreatic adenocarcinoma and are better correlated with overall survival than traditional circulating tumor […]